-
Fall Hot Streak Continues With Solid Launches For ABC's 'Designated Survivor' And Fox's 'Lethal Weapon'
Friday, September 23, 2016 - 8:59am | 395Read More...The major networks are very optimistic so far this new fall season, as every new show has launched above a 2.0 in the all-important 18–49 demo. Wednesday, the streak continued as ABC (Walt Disney Co (NYSE: DIS)) and Fox Twenty-First Century Fox Inc (NASDAQ: FOXA)) saw continued success. ABC...
-
What Investors Need To Know About The CW's New 2016 Fall Season
Wednesday, September 14, 2016 - 8:39am | 832Read More...It is that time of the year again where the networks reboot themselves with a brand new schedule and a brand new crop of rookie series. For investors it is an important period as it can give them a snapshot of how the network will do over the next season and in many cases how that will impact the...
-
What Investors Need To Know About Fox's New 2016 Fall Season
Monday, September 12, 2016 - 11:54am | 821Read More...It is that time of the year again where the networks reboot themselves with a brand new schedule and a brand new crop of rookie series. For investors it is an important period as it can give them a snapshot of how the network will do over the next season and in many cases how that will impact the...
-
Technology Forces Advertisers To Get Creative
Wednesday, June 22, 2016 - 2:12pm | 409Read More...The days of 30-second TV commercials may be numbered. According to the Wall Street Journal’s Suzanne Vranica, commercial-free streaming video content, DVRs and ad-blocking software have forced advertisers to re-think their approach to consumers. Two of the most popular new approaches involve...
-
Fox Announces 6 New Pickups, Including 'Pitch' and 'Lethal Weapon'
Thursday, May 12, 2016 - 1:24pm | 220Read More...The other week, Twenty-First Century Fox Inc (NASDAQ: FOXA) started its shopping for the 2016–2017 season by officially greenlighting "24" reboot "Legacy" and "Empire" co-creator Lee Daniels' newest project "Star." On Tuesday, executives gave six more shows the good news, including four...
-
Fox Stabilizes Roster With Renewals Of Freshman Hits 'Lucifer' And 'Rosewood'
Monday, April 11, 2016 - 8:34am | 351Read More...Despite strong buzz for its freshman class, Twenty-First Century Fox Inc (NASDAQ: FOXA)'s fall season for the second straight year got off to a rough start. However, a pair of surprise hits have once again come to the rescue, and the network on Thursday ensured they'd be back for an encore. "...
-
'X-Files' Relaunch Continues To Yield Positive Results For Fox
Tuesday, February 2, 2016 - 3:04pm | 471Read More...As it turns out, "the truth" is still out there; and so are millions of viewers who clearly missed the iconic Twenty-First Century Fox Inc (NASDAQ: FOXA) series that made the phrase popular. Looking At The Numbers Originally, the first episode of the "X-Files" reboot debuted to a strong 18–49...
-
Debut Ratings Of 'X-Files' And 'Lucifer' Give Fox A Powerful Monday Night Lineup
Wednesday, January 27, 2016 - 10:16am | 399Read More...Twenty-First Century Fox Inc (NASDAQ: FOXA)'s "The X-Files" picked up right where it left off Sunday night and kept the momentum going into its new Monday night timeslot. Initial numbers from the re-launch of the iconic Emmy winning series showed "The X-Files" gained from early data in both viewers...
-
Fox Gets Nostalgic As Executives Discuss '24,' 'Prison Break' And 'X-Files' Returns
Tuesday, January 19, 2016 - 9:46am | 483Read More...Twenty-First Century Fox Inc (NASDAQ: FOXA)'s day at the winter edition of the Television Critics Association on Friday marks the final of the big four broadcast networks to take their turn in the spotlight, but that didn't make it any less interesting. The network's co-heads Gary Newman and Dana...
-
Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside
Tuesday, January 12, 2016 - 11:45am | 409Read More...Amid volatility, Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) shares have declined 21 percent over the past six months. Empire’s Dr. Cathy Reese initiating coverage of the company with a Sell rating and a price target of $7. The company has only one FDA approved drug, which could...










